Genome & Company Sets Record Date for Extraordinary General Meeting

Genome & Company announced via board resolution on July 10, 2026 that it has set July 27, 2026 as the record date to determine shareholders entitled to vote at the extraordinary general meeting.
Due to the electronic registration system, there is no closure of the shareholder registry. This is a routine administrative procedure.
There are no capital changes or dividend-related matters. This record date setting has no direct impact on shareholder value.
[AI Summary]The record date setting for the EGM is a standard corporate action with no changes to capital structure or dividend policy, making it neutral for shareholder value.